The Hill: NIH funding cuts imperil lifesaving drugs and US prosperity
Professor Jennifer S. Bard, University of Cincinnati College of Law, recently co-authored an opinion editorial for The Hill concerning the health and economic benefits of National Institute of Health (NIH) funding and the societal impact of reducing its funding. The editorial, co-authored by Professor Lawrence Gostin, O’Neill Institute for National and Global Health Law at Georgetown University and Director of the World Health Organization Center on Global Health Law, explained what the co-authors believe to be the critical importance of government funding to the work of the NIH, the historical success of the NIH’s work supported through government funding, and the potentially negative impact of a loss of funding, particularly to support vital clinical studies.
Wrote the authors, “The NIH funds basic “high-risk and pre-commercial research” that no private capital venture or pharmaceutical company would invest in due to the long horizon for finding cures. Across the board — from Alzheimer’s disease to cancer and heart disease — NIH’s funding of basic research has turned out to be a spectacularly successful investment.”
They noted that a recent study found that the NIH supported 354 out of 356 drugs approved from 2010-2019. “That means that most of the lifesaving medications we take for granted today would not have been possible without the NIH.”
The authors go on to discuss the impact of funding reduction, including decimating biomedical research, the potential job loss for thousands of highly trained researchers, and the negative impact on patients currently enrolled in clinical trials who would lose access to those cutting-edge treatments.
Concluded Bard and Gostin, “The NIH funding model has made the U.S. the world’s science superpower and our universities the premier destination for students from every nation. Slashing NIH funding will not save money, but it will unravel a biomedical system that has powered our economy and protected our population for generations.”
Read the entire editorial here: NIH funding cuts imperil lifesaving drugs and US prosperity
Learn more about Professor Jennifer S. Bard and her scholarship.
Learn more about Professor Lawrence Gostin and his scholarship.
Lead photo: instockphoto.com
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.